<!DOCTYPE html>
<html id="mobile">
<head>
    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=2, user-scalable=yes" />
    <!--Needs to be scalable yes for previous versions of android and select-->

    <title></title>
    <link href='stylesheets/fonts.css' rel='stylesheet' type='text/css'>
    <link rel="stylesheet" href="stylesheets/mobile.css">
    <link rel="stylesheet" href="stylesheets/responsive-tables.css">
    <script src="javascripts/jquery.min.js"></script>
    <script src="javascripts/responsive-tables.js"></script>
</head>
<body>
    <div id="main">
        <div class="content">
            <div class="content">
                <h6>Table 1. Distinguishing features of muscular dystrophies</h6>
            </div>
        </div>
    </div>

    <table class="responsive">
        <thead>
            <tr>
                <th>Designation</th>
                <th>Protein</th>
                <th>Chromosome</th>
                <th>Inheritance</th>
                <th>Common patterns of weakness</th>
                <th>Distinguishing clinical features</th>
                <th>Distinguishing EMG and muscle biopsy features</th>
                <th>Complications</th>
            </tr>
        </thead>
        <tr class=sub-header-row>
            <td class="sub-header">X-linked muscular dystrophies</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr>
            <td>EDMD-X1</td>
            <td>Emerin</td>
            <td>Xq28</td>
            <td>XR</td>
            <td>HP</td>
            <td>Contractures invariably present early in the disease course</td>
            <td></td>
            <td>Cardiac conduction abnormalities</td>
        </tr>
        <tr>
            <td>EDMD-X2</td>
            <td>FHL1</td>
            <td>Xq27.2</td>
            <td>XR</td>
            <td>LG, HP or SP, DM</td>
            <td>Foot drop; extremity contractures and neck contractures common</td>
            <td>Myofibrillar myopathy or reducing bodies</td>
            <td>Severe respiratory failure in many patients</td>
        </tr>
        <tr>
            <td>Becker muscular dystrophy</td>
            <td>Dystrophin</td>
            <td>Xp21</td>
            <td>XR</td>
            <td>LG</td>
            <td>Calf hypertrophy</td>
            <td>Mosaic appearance of dystrophin on immunohistochemistry in affected woman</td>
            <td>Dilated cardiomyopathy in 4% to 70% depending on disease duration</td>
        </tr>
        <tr class=sub-header-row>
            <td class="sub-header">Limb-girdle muscular dystrophies (LGMDs)</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr>
            <td>LGMD1A</td>
            <td>Myotilin</td>
            <td>5q22.3-31.3</td>
            <td>AD</td>
            <td>LG, DM</td>
            <td>Onset > 40 years, foot drop, asymmetric muscle weakness and atrophy</td>
            <td>Myofibrillar myopathy, myotonic or pseudomyotonic discharges</td>
            <td>Cardiomyopathy, respiratory muscle weakness</td>
        </tr>
        <tr>
            <td>LGMD1B</td>
            <td>Lamin A/C</td>
            <td>1q11-21</td>
            <td>AD</td>
            <td>LG, HP, DM</td>
            <td>Early humeroperoneal weakness, limb contractures</td>
            <td></td>
            <td>Cardiomyopathy and conduction system disease</td>
        </tr>
        <tr>
            <td>LGMD1C</td>
            <td>Caveolin-3</td>
            <td>
                3p25
            </td>
            <td>
                AD
            </td>
            <td>
                LG
            </td>
            <td>
                Rippling muscles, percussion-induced rapid contractions, prominent muscle cramps and calf hypertrophy
            </td>
            <td></td>
            <td></td>
        </tr>
        <tr>
            <td>
                LGMD1D
            </td>
            <td>
                DNAJB6
            </td>
            <td>
                6q23
            </td>
            <td>
                AD
            </td>
            <td>
                LG, DM
            </td>
            <td>
                Onset > 40 years, foot drop
            </td>
            <td>
                Myofibrillar myopathy, rimmed vacuoles, myotonic or pseudomyotonic discharges
            </td>
            <td></td>
        </tr>
        <tr>
            <td>
                LGMD1E
            </td>
            <td>
                Desmin
            </td>
            <td>
                2q35
            </td>
            <td>
                AD
            </td>
            <td>
                LG, HP, DM
            </td>
            <td>
                Onset < 40 years, foot drop
            </td>
            <td>
                Myofibrillar myopathy, myotonic or pseudomyotonic discharges
            </td>
            <td>
                Cardiomyopathy, respiratory muscle weakness
            </td>
        </tr>
        <tr>
            <td>
                LGMD2A
            </td>
            <td>
                Calpain-3
            </td>
            <td>
                15q15.1-21.1
            </td>
            <td>
                AR
            </td>
            <td>
                LG
            </td>
            <td>
                "More common in patients with British, Southern or Eastern European, or Brazilian ancestry; scapular winging; absence
                of calf hypertrophy"
            </td>
            <td>
                Inflammatory changes on some biopsies
            </td>
            <td></td>
        </tr>
        <tr>
            <td>
                LGMD2B
            </td>
            <td>
                Dysferlin
            </td>
            <td>
                2p13
            </td>
            <td>
                AR
            </td>
            <td>
                LG, DM (Miyoshi phenotype)
            </td>
            <td>
                Calf atrophy, inability to stand on toes
            </td>
            <td></td>
            <td>Left ventricular hypertrophy or reduced ejection fraction in rare patients</td>
        </tr>
        <tr>
            <td>LGMD2C</td>
            <td>&#947;-Sarcoglycan</td>
            <td>13q12</td>
            <td>AR</td>
            <td>LG</td>
            <td>Age of onset 2 to 23 years; macroglossia, ankle contractures, and scoliosis</td>
            <td></td>
            <td>Severe ventilatory muscle weakness has been reported in up to one-third of patients</td>
        </tr>
        <tr>
            <td>LGMD2D</td>
            <td>&#945;-Sarcoglycan</td>
            <td>17q12-21.3</td>
            <td>AR</td>
            <td>LG</td>
            <td></td>
            <td></td>
            <td></td>
        </tr>
        <tr>
            <td>LGMD2E</td>
            <td>&#946;-Sarcoglycan</td>
            <td>4q12</td>
            <td>AR</td>
            <td>LG</td>
            <td></td>
            <td></td>
            <td></td>
        </tr>
        <tr>
            <td>LGMD2F</td>
            <td>&#948;-Sarcoglycan</td>
            <td>5q33-34</td>
            <td>AR</td>
            <td>LG</td>
            <td>Early age of onset, 4 to 10 years</td>
            <td></td>
            <td>Early respiratory muscle involvement</td>
        </tr>
        <tr>
            <td>LGMD2G</td>
            <td>Telethonin</td>
            <td>17q11-12</td>
            <td>AR</td>
            <td>LG</td>
            <td></td>
            <td>Rimmed vacuoles</td>
            <td>Cardiac involvement, type unspecified</td>
        </tr>
        <tr>
            <td>LGMD2H</td>
            <td>E3-ubiquitin- ligase (TRIM32)</td>
            <td>9q31-33</td>
            <td>AR</td>
            <td></td>
            <td>Hutterite descent</td>
            <td>Many small vacuoles usually more prominent in type II fibers</td>
            <td></td>
        </tr>
        <tr>
            <td>LGMD2I</td>
            <td>Fukutin-related protein (FKRP)</td>
            <td>19q13</td>
            <td>AR</td>
            <td>LG</td>
            <td>Northern European ancestry, scapular winging, calf hypertrophy, early cardiorespiratory involvement</td>
            <td></td>
            <td>Dilated cardiomyopathy and respiratory dysfunction common</td>
        </tr>
        <tr>
            <td>LGMD2J</td>
            <td>Titin</td>
            <td>2q31</td>
            <td>AR</td>
            <td>LG</td>
            <td>Finnish and French populations</td>
            <td>Rimmed vacuoles</td>
            <td></td>
        </tr>
        <tr>
            <td>LGMD2K</td>
            <td>POMT1</td>
            <td>9q31</td>
            <td>AR</td>
            <td>LG</td>
            <td></td>
            <td></td>
            <td></td>
        </tr>
        <tr>
            <td>LGMD2L</td>
            <td>Anoctamin-5</td>
            <td>11p14.3</td>
            <td>AR</td>
            <td>LG, DM (Miyoshi phenotype)</td>
            <td>Calf atrophy, inability to stand on toes</td>
            <td></td>
            <td></td>
        </tr>
        <tr>
            <td>LGMD2M (fukutin)</td>
            <td>Fukutin</td>
            <td>9q31-33</td>
            <td>AR</td>
            <td></td>
            <td>Early age of onset, 4 months to 4 years</td>
            <td></td>
            <td>Some muscle biopsies with prominent inflammatory changes</td>
        </tr>
        <tr>
            <td>LGMD2N</td>
            <td>POMT2</td>
            <td>14q24</td>
            <td>AR</td>
            <td>LG</td>
            <td></td>
            <td></td>
            <td></td>
        </tr>
        <tr>
            <td>LGMD2O</td>
            <td>POMGNT1</td>
            <td>1p32</td>
            <td>AR</td>
            <td>LG</td>
            <td></td>
            <td></td>
            <td></td>
        </tr>
        <tr>
            <td>LGMD2P</td>
            <td>&#945;-Dystroglycan</td>
            <td>3p21</td>
            <td>AR</td>
            <td>LG</td>
            <td></td>
            <td></td>
            <td></td>
        </tr>
        <tr>
            <td>LGMD2Q</td>
            <td>Plectin</td>
            <td>8q24.3</td>
            <td>AR</td>
            <td>LG</td>
            <td>History of epidermolysis bullosa; pyloric atresia seen in other forms of plectinopathies, although not in LGMD2Q</td>
            <td></td>
            <td></td>
        </tr>
        <tr class="sub-header-row">
            <td class="sub-header">Myofibrillar myopathies</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr>
            <td>Myotilinopathy (LGMD1A)</td>
            <td>Myotilin</td>
            <td>5q22.3-31.3</td>
            <td>AD</td>
            <td>LG, DM</td>
            <td>Onset > 40 years, foot drop, asymmetric muscle weakness and atrophy</td>
            <td>Myofibrillar myopathy, myotonic or pseudomyotonic discharges</td>
            <td>Cardiomyopathy, respiratory muscle weakness</td>
        </tr>
        <tr>
            <td>Desminopathy (LGMD1E)</td>
            <td>Desmin</td>
            <td>2q35</td>
            <td>AD</td>
            <td>LG, HP, DM</td>
            <td>Onset < 40 years, foot drop</td>
            <td>Myofibrillar myopathy, myotonic or pseudomyotonic discharges</td>
            <td>Cardiomyopathy, respiratory muscle weakness</td>
        </tr>
        <tr>
            <td>Titinopathy (HMERF)</td>
            <td>Titin</td>
            <td>2q31</td>
            <td>AD</td>
            <td>LG</td>
            <td>Finnish and French populations</td>
            <td>Rimmed vacuoles, myofibrillar myopathy</td>
            <td>Autosomal dominant, early respiratory failure</td>
        </tr>
        <tr>
            <td>BAG3</td>
            <td>BCL2-associated athanogene 3</td>
            <td>10q25.2-q26.2</td>
            <td>AD</td>
            <td>LG, DM</td>
            <td>Onset < 40 years, foot drop</td>
            <td>Myofibrillar myopathy, myotonic or pseudomyotonic discharges</td>
            <td>Cardiomyopathy, respiratory muscle weakness</td>
        </tr>
        <tr>
            <td>Filamin C (Williams distal myopathy)</td>
            <td>Filamin C</td>
            <td>7q32.1</td>
            <td>AD</td>
            <td>LG, DM</td>
            <td>Onset > 40 years, foot drop</td>
            <td>Myofibrillar myopathy, myotonic or pseudomyotonic discharges</td>
            <td>Cardiomyopathy, respiratory muscle weakness</td>
        </tr>
        <tr>
            <td>&#945;B-Crystallin</td>
            <td>&#945;B-Crystallin</td>
            <td>11q21-23</td>
            <td>AD</td>
            <td>LG, DM</td>
            <td>Early or late onset, foot drop</td>
            <td>Myofibrillar myopathy, myotonic or pseudomyotonic discharges</td>
            <td>Cardiomyopathy, respiratory muscle weakness</td>
        </tr>
        <tr>
            <td>ZASP</td>
            <td>Z-band alternatively spliced PDZ motif-containing protein</td>
            <td>10q22.3-23.2</td>
            <td>AD</td>
            <td>LG, DM</td>
            <td>Onset > 40 years, foot drop</td>
            <td>Myofibrillar myopathy, myotonic or pseudomyotonic discharges</td>
            <td>Cardiomyopathy, respiratory muscle weakness</td>
        </tr>
        <tr>
            <td>FHL1</td>
            <td>Four-and-one-half LIM1 protein</td>
            <td>Xq27.2</td>
            <td>X-linked</td>
            <td>LG, HP or SP, DM</td>
            <td>Foot drop; extremity contractures and neck contractures common</td>
            <td>Myofibrillar myopathy or reducing bodies</td>
            <td>Severe respiratory failure in many patients</td>
        </tr>
        <tr class="sub-header-row">
            <td class="sub-header">Hereditary inclusion body myopathy (hIBM)</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr>
            <td>AR hIBM</td>
            <td>Glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmanno- samine kinase (GNE)</td>
            <td></td>
            <td>AR</td>
            <td>DM</td>
            <td>Early adult onset, foot drop</td>
            <td>Rimmed vacuoles</td>
            <td></td>
        </tr>
        <tr>
            <td>AD hIBMPFD</td>
            <td>Valosin- containing protein (VCP)</td>
            <td></td>
            <td>AD</td>
            <td>LG, DM</td>
            <td>Proximal and distal weakness; past or family history of frontotemporal dementia, Paget disease, motor neuron disease</td>
            <td>Rimmed vacuoles, myotonic discharges</td>
            <td></td>
        </tr>
        <tr>
            <td>hIBM3</td>
            <td>MYHC-IIA</td>
            <td></td>
            <td>AD</td>
            <td>LG</td>
            <td>External ophthalmoplegia, joint contractures</td>
            <td>Rimmed vacuoles, lobulated fibers, absent type IIA fibers</td>
            <td></td>
        </tr>
        <tr class="sub-header-row">
            <td class="sub-header">Distal dystrophies/myopathies</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr>
            <td>Welander distal myopathy</td>
            <td>TIA1</td>
            <td>2p13</td>
            <td>AD</td>
            <td>DM</td>
            <td>Swedish/Finnish ancestry, late adult onset, index finger and wrist extensor weakness followed by atrophy of hand muscles</td>
            <td></td>
            <td></td>
        </tr>
        <tr>
            <td>Udd distal myopathy</td>
            <td>Titin</td>
            <td>2q31</td>
            <td>AR, AD</td>
            <td>LG, DM</td>
            <td></td>
            <td></td>
            <td>Some phenotypes with early respiratory failure or early dilated cardiomyopathy</td>
        </tr>
        <tr>
            <td>Markesbery- Griggs</td>
            <td>Z-band alternatively spliced PDZ motif-containing protein (ZASP)</td>
            <td>10q22.3-23.2</td>
            <td>AD</td>
            <td>LG, DM</td>
            <td>Onset > 40 years, foot drop</td>
            <td>Myofibrillar myopathy, myotonic or pseudomyotonic discharges</td>
            <td>Cardiomyopathy, respiratory muscle weakness</td>
        </tr>
        <tr>
            <td>Laing, hyaline body myopathy</td>
            <td>MYH7, myosin heavy chain</td>
            <td>14q11</td>
            <td>AD</td>
            <td>DM</td>
            <td>Early adult onset,  foot drop, neck weakness, disabling myalgias, calf hypertrophy</td>
            <td></td>
            <td>Cardiomyopathy</td>
        </tr>
        <tr>
            <td>Williams distal myopathy</td>
            <td>Filamin C</td>
            <td>7q32.1</td>
            <td>AD</td>
            <td>LG, DM</td>
            <td>Onset > 40 years, foot drop</td>
            <td>Myofibrillar myopathy, myotonic or pseudomyotonic discharges</td>
            <td>Cardiomyopathy, respiratory muscle weakness</td>
        </tr>
        <tr>
            <td>Vocal cord and pharyngeal weakness with distal myopathy (VCPDM)</td>
            <td>Matrin-3</td>
            <td>5q31.2</td>
            <td>AD</td>
            <td>DM</td>
            <td>Mean age at onset 45 years, foot drop and distal upper extremity weakness, dysphagia, dysphonia</td>
            <td>Subsarcolemmal rimmed vacuoles</td>
            <td></td>
        </tr>
        <tr>
            <td>Distal myopathy with Kelch-like homologue 9 mutations</td>
            <td>Kelch-like 9</td>
            <td>9p22</td>
            <td>AD</td>
            <td>DM</td>
            <td></td>
            <td></td>
            <td></td>
        </tr>
        <tr>
            <td>Miyoshi myopathy type I, LGMD2B</td>
            <td>Dysferlin</td>
            <td>2p13</td>
            <td>AR</td>
            <td>DM (Miyoshi phenotype)</td>
            <td>Calf atrophy, inability to stand on toes</td>
            <td></td>
            <td>Left ventricular hypertrophy or reduced ejection fraction in rare patients</td>
        </tr>
        <tr>
            <td>Miyoshi myopathy type III, LGMD2L</td>
            <td>Anoctamin-5</td>
            <td>11p14.3</td>
            <td>AR</td>
            <td>DM (Miyoshi phenotype)</td>
            <td>Calf atrophy, inability to stand on toes</td>
            <td></td>
            <td></td>
        </tr>
        <tr>
            <td>Nonaka myopathy, AR hIBM</td>
            <td>Glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmanno- samine kinase (GNE)</td>
            <td></td>
            <td>AR</td>
            <td>DM</td>
            <td>Early adult onset, foot drop</td>
            <td>Rimmed vacuoles</td>
            <td></td>
        </tr>
        <tr>
            <td>Nebulin myopathy</td>
            <td>Nebulin</td>
            <td>2q21.2-q22</td>
            <td>AR</td>
            <td>DM</td>
            <td>Early adult onset, foot drop</td>
            <td>Nemaline rods</td>
            <td></td>
        </tr>
        <tr class="sub-header-row">
            <td class="sub-header">Other dystrophies</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
            <td>&nbsp;</td>
        </tr>
        <tr>
            <td>Bethlem myopathy</td>
            <td>Collagen VI</td>
            <td></td>
            <td>AD</td>
            <td>HP</td>
            <td>Joint laxity, prominent calcanei, variable age of onset</td>
            <td></td>
            <td></td>
        </tr>
        <tr>
            <td>Ullrich myopathy</td>
            <td>Collagen VI</td>
            <td></td>
            <td>AR</td>
            <td>HP</td>
            <td>Joint laxity, prominent calcanei, neonatal or congenital onset</td>
            <td></td>
            <td></td>
        </tr>
        <tr>
            <td>Selenoprotein N1 (rigid spine syndrome)*</td>
            <td>Selenoprotein N1</td>
            <td>1p36</td>
            <td>AR</td>
            <td>LG</td>
            <td>Rigid spine, joint contractures, generalized weakness</td>
            <td>Multiminicores, cores, Mallory bodies, type I fiber predominance</td>
            <td>Restrictive lung disease</td>
        </tr>
        <tr>
            <td>Muscular dystrophy with generalized lipodystrophy</td>
            <td>Cavin-1/PTRF</td>
            <td>17q21.2</td>
            <td>AR</td>
            <td>Distal dominant, generalized</td>
            <td>Generalized lipodystrophy, myalgia, cramps, percussion-induced muscle mounding, hepatosplenomegaly, insulin resistance, acanthosis nigricans</td>
            <td></td>
            <td>Arrhythmias including prolonged QT syndrome, sudden cardiac death</td>
        </tr>
    </table>
    <!--<div class="scrollable sticky-header">
        <table id="fixed-scrolling-header"></table>
    </div>
    <div class="pinned sticky-header">
        <table id="fixed-header"></table>
    </div>-->
    <p style="padding:12px;">
        Abbreviations: AD = autosomal dominant; AR = autosomal  recessive;  DM = distal muscular; EDMD = Emery-Dreifuss muscular dystrophy;
        hIBMPFD = hIBM with Paget disease and frontotemporal dementia; HMERF = hereditary myopathy with early respiratory failure; HP = humeroperoneal; LG = limb-girdle;  PTRF = polymerase I and transcript release  factor; SP = scapuloperoneal; XR = X-linked recessive
    </p>
    <p style ="padding:12px;">
        *Rigid spine syndrome can also be caused  by FHL1, BAG3, lamin A/C, and collagen VI mutations.
    </p>
    <p style="padding:12px;">
        LGMD 2R and 2S were described after this systematic review was performed and hence are not discussed in this guideline.
    </p>
    
    <div id="footer">
        <div id="copyright">&copy;2014 American Academy of Neurology - All rights reserved.</div>
    </div>
</body>
</html>
